Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.

Detaylı Bibliyografya
Asıl Yazarlar:	Potter, M, Grace, S, Teehan, C, Ethell, M, Theocharous, P, Claude, R, Hale, G, Waldmann, H, Prentice, H
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2000

Benzer Materyaller

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
Yazar:: Kottaridis, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Bone marrow GvHD after allogeneic hematopoietic stem cell transplantation
Yazar:: Martin eSzyska, ve diğerleri
Baskı/Yayın Bilgisi: (2016-03-01)

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation
Yazar:: Mauro Di Ianni, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
Yazar:: Raffaella Greco, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
Yazar:: Fibbe, W, ve diğerleri
Baskı/Yayın Bilgisi: (1993)

The Role of Bacteria and Pattern Recognition Receptors in GvHD
Yazar:: E. Holler, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1988)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
Yazar:: Hemn Mohammadpour, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1996)

In marrow aplasia reduced-intensity conditioning and T-cell depletion of cytokine mobilised stem cells provides good engraftment without GvHD
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD
Yazar:: Jongbok Lee, ve diğerleri
Baskı/Yayın Bilgisi: (2025-01-01)

Modulation of T-regulatory cells by small molecules: potential therapy for GvHD
Yazar:: Leuschner, U
Baskı/Yayın Bilgisi: (2021)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
Yazar:: Kudakwashe Mhandire, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Effective Extracorporeal Photopheresis of Patients with Transplantation Induced Acute Intestinal GvHD and Bronchiolitis Obliterans Syndrome
Yazar:: Robin Reschke, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

The role of animal models in the study of hematopoietic stem cell transplantation and GvHD: A historical overview.
Yazar:: Margherita Boieri, ve diğerleri
Baskı/Yayın Bilgisi: (2016-08-01)

Effect of the YCD3-1 Anti-Mouse Monoclonal on Murine GvHD
Yazar:: James P. Okunewick, ve diğerleri
Baskı/Yayın Bilgisi: (1993-07-01)

Quality of life of patients with graft-versus-host disease (GvHD) post-hematopoietic stem cell transplantation
Yazar:: Sibéli de Fátima Ferraz Simão Proença, ve diğerleri

The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD following Hematopoietic Stem Cell Transplantation
Yazar:: Seyed Asadollah Mousavi, ve diğerleri
Baskı/Yayın Bilgisi: (2016-12-01)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Yazar:: Chakrabarti, S, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
Yazar:: Ines Bojanic, ve diğerleri
Baskı/Yayın Bilgisi: (2023-02-01)

Antigen-specific priming is dispensable in depletion of apoptosis-sensitive T cells for GvHD prophylaxis
Yazar:: Shai eYarkoni, ve diğerleri
Baskı/Yayın Bilgisi: (2014-05-01)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Yazar:: Novitzky, N, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

HLA and Non-HLA Factors for Donor Selection in Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide GvHD Prophylaxis
Yazar:: Hiroko Shike, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

INVITRO TREATMENT OF MARROW WITH ATCG OR CAMPATH-1 FOR PROPHYLAXIS OF GVHD - RESULTS OF THE AG-KMT MUNCHEN
Yazar:: Kolb, H, ve diğerleri
Baskı/Yayın Bilgisi: (1985)

Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival
Yazar:: Lambros Kordelas, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

CAMPATH-1 antibodies in stem-cell transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Availability of Campath-1 antibodies for bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis
Yazar:: Massimo Berger, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Spontaneous xenogeneic GvHD in Wilms' tumor Patient‐Derived xenograft models and potential solutions
Yazar:: Seyed Mostafa Monzavi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

Correction to: Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial
Yazar:: Roberto Crocchiolo, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy
Yazar:: Regina Jitschin, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD
Yazar:: Weijia Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells
Yazar:: Haroon Shaikh, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

FTY720 ameliorates GvHD by blocking T lymphocyte migration to target organs and by skin fibrosis inhibition
Yazar:: Jaeyoon Ryu, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

3120 Probable multifocal central nervous system graft-versus-host disease (CNS GvHD) with concurrent cerebellitis following allogenic stem-cell transplant (ASCT) for T-cell leukemia
Yazar:: Deepti Dr Yagnik
Baskı/Yayın Bilgisi: (2024-08-01)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
Yazar:: Russell, N, ve diğerleri
Baskı/Yayın Bilgisi: (1999)

Ceruloplasmin is a potential biomarker for aGvHD following allogeneic hematopoietic stem cell transplantation.
Yazar:: Meng Lv, ve diğerleri
Baskı/Yayın Bilgisi: (2013-01-01)

CAMPATH: from concept to clinic.
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (2005)